Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition

Menopause

Volumn 17, Issue 4, 2010, Pages 815-822

  Maki, Pauline M ^a   Freeman, Ellen W ^b   Greendale, Gail A ^c   Henderson, Victor W ^d   Newhouse, Paul A ^e   Schmidt, Peter J ^f   Scott, Nelda F ^g   Shively, Carol A ^h   Soares, Claudio N ⁱ  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g Department of Emergency Medicine   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

Cognition; Depression; Menopause; Mood; Perimenopause

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIENOGEST; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GONADORELIN AGONIST; NORETHISTERONE ACETATE; CHOLINERGIC RECEPTOR;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLINERGIC SYSTEM; CLIMACTERIUM; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; ESTROGEN THERAPY; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HYPOGONADISM; MEMORY; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MILD COGNITIVE IMPAIRMENT; POSTMENOPAUSE; REVIEW; SIDE EFFECT; VERBAL MEMORY; AGING; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COGNITION DISORDERS; FEMALE; HORMONE SUBSTITUTION; MENOPAUSE; NATIONAL HEALTH ORGANIZATION; NERVE CELL; ORGANIZATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RISK; RISK FACTOR; UNITED STATES;

AGING; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; CONGRESSES AS TOPIC; DEPRESSION; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; NATIONAL INSTITUTE ON AGING (U.S.); NEURONS; RECEPTORS, CHOLINERGIC; RISK; RISK FACTORS; UNITED STATES;

EID: 77954948745     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181d763d2     Document Type: Review

References (37)

1. Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006;67: 1422-1427.
2. Cizza G, Primma S, Csako G. Depression as a risk factor for osteo-porosis. Trends Endocrinol Metab 2009;20:367-373.
3. Perez-Lopez FR, Chedraui P, Gilbert JJ, Perez-Roncero G. Cardiovas-cular risk in menopausal women and prevalent related co-morbid condi-tions: facing the postYWomen's Health Initiative era. Fertil Steril 2009; 92:1171-1186
4. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142:1003-1013.
5. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
6. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hor-mones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382.
7. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390.
8. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord 2007;103:267-272.
9. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238-2244.
10. Ryan J, Burger HG, Szoeke C, et al. A prospective study of the asso-ciation between endogenous hormones and depressive symptoms in postmenopausal women. Menopause 2009;16:509-517.
11. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58:529-534.
12. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. Short-term use of estradiol for depression in perimenopausal and post-menopausal women: a preliminary report. Am J Psychiatry 2003;160: 1519-1522.
13. Harsh VL, Fortinsky P, Gearhart TF, Rubinow DR, Schmidt PJ. Effects of Induced Hypogonadism on Mood and Behavior in Healthy Women, Washington, DC: American Psychiatric Association, 2008.
14. Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety 1998;7: 171-177.
15. Steingold KA, Cedars M, Lu JK, Randle D, Judd HL, Meldrum DR. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol 1987;69:403-411.
16. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
18. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:765-776.
19. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA 1999;282:1737-1744.
20. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613.
21. Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 2004;42:1194-1201.
22. Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-249.
23. Shively CA, Musselman DL, Willard SL. Stress, depression, and coro-nary artery disease: modeling comorbidity in female primates. Neurosci Biobehav Rev 2009;33:133-144.
24. Mitchell E, Woods N. Midlife women's attributions about perceived memory changes: observations from the Seattle Midlife Women's Health Study. J Womens Health Gend Based Med 2001;10:351-362.
25. Henderson V, Guthrie J, Dudley E, Burger H, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women. Neurology 2003;60:1369-1371.
26. Fuh JL, Wang SJ, Lee SJ, Lu SR, Juang KD. A longitudinal study of cognition change during early menopausal transition in a rural com-munity. Maturitas 2006;53:447-453.
27. Meyer PM, Powell LH, Wilson RS, et al. A population-based lon-gitudinal study of cognitive functioning in the menopausal transition. Neurology 2003;61:801-806.
28. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 2009;72:1850-1857.
29. Maki PM. Menopause and cognition. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 3rd ed. San Diego, CA: Academic Press, 2007:279-293.
30. Maki PM, Sundermann E. Hormone therapy and cognitive function. Hum Reprod Update 2009;15:667-681.
31. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in peri-menopausal and recently postmenopausal women. Menopause 2006;13: 411-422.
32. Linzmayer L, Semlitsch HV, Saletu B, et al. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 2001;51:238-245.
33. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology 2009;34:1065-1074.
34. Espeland M, Rapp S, Shumaker S, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-2968. (Pubitemid 38802685)
35. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 2005;192:387-393.
36. Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. Neuropsychopharmacology 2006;31: 2065-2078.
37. Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estradiol interacts with the cholinergic system to affect verbal memory in post-menopausal women: evidence for the critical period hypothesis. Horm Behav 2008;53:159-169.